Primary endpoint (between 16 and 24 months) |
DAS<1.6, SJC44<1, ΔvdHSS<0.5, n (%) | 26 (22.0%) | 21 (18.8%) | 3.3 (−7.1 to 13.7) | 0.54 |
Components of primary endpoint* and secondary outcomes |
*No swollen joints 16–24 months, n (%) | 62 (52.5%) | 61 (54.5%) | −1.9 (−14.8 to 11.0) | 0.77 |
*DAS remission (DAS<1.6) 16–24 months, n (%) | 64 (54.2%) | 58 (51.8%) | 2.5 (−10.4 to 15.4) | 0.71 |
*No radiographic progression 16–24 months, n (%) | 49 (41.5%) | 39 (34.8%) | 6.7 (−5.8 to 19.2) | 0.29 |
DAS remission (DAS<1.6) at 24 months, n (%) | 80 (67.8%) | 75 (67.0%) | 0.8 (−11.3 to 13.0) | 0.89 |
SDAI remission (SDAI<3.3) at 24 months, n (%) | 71 (60.2%) | 56 (50.0%) | 10.2 (−2.6 to 23.0) | 0.12 |
EULAR good/moderate response at 24 months, n (%) | 98 (83.1%) | 90 (80.4%) | 2.7 (−7.3 to 12.7) | 0.60 |
Δ Modified Sharp score at 24 months, median (p25, p75) | 1.0 (0, 2.5) | 1.5 (0.5, 3.0) | −0.45 (−0.90 to 0) | 0.05 |
Treatment at end of study |
MTX monotherapy, n (%) | 63 (53.4%) | 80 (71.4%) | −18.0 (−30.3 to −5.8) | 0.004 |
MTX/SSZ/HCQ combination therapy, n (%) | 21 (17.8%) | 13 (11.6%) | 6.2 (−2.9 to 15.3) | 0.18 |
Biologic treatment, n (%) | 34 (28.8%) | 19 (17.0%) | 11.8 (1.1 to 22.6) | 0.03 |